QbD-Based Development of Translabial Bupropion-Loaded Nanoemulstick for Brain-Targeted Dopamine Modulation in Smoking Cessation using PC12 Cell Lines
- 14 July 2025
- journal article
- research article
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 20 (4) , 1-18
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Formulation development of pharmaceutical nanoemulgel for transdermal delivery of feboxostat: Physical characterization and in vivo evaluationEuropean Journal of Pharmaceutical Sciences, 2023
- Design, Characterization and Optimization of Solid Lipid Nanoparticles of Bupropion by Using 23 Factorial DesignPharmaceutical Chemistry Journal, 2023
- Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): A risk based industrial approachBiomedicine & Pharmacotherapy, 2021
- Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical PracticeHigh Blood Pressure & Cardiovascular Prevention, 2020
- Implementation of Quality by Design (QbD) approach in development of silver sulphadiazine loaded egg oil organogel: An improved dermatokinetic profile and therapeutic efficacy in burn woundsInternational Journal of Pharmaceutics, 2020
- Lanolin-based organogel of salicylic acid: evidences of better dermatokinetic profile in imiquimod-induced keratolytic therapy in BALB/c mice modelDrug Delivery and Translational Research, 2017
- A novel translabial platform utilizing bioexcipients from Litchi chinesis for the delivery of rosiglitazone maleateActa Pharmaceutica Sinica B, 2013
- Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosaEuropean Journal of Pharmaceutical Sciences, 2013
- Cell Sensitivity Assays: The MTT Assay2011
- Transdermal delivery of anticancer drug caffeine from water-in-oil nanoemulsionsColloids and Surfaces B: Biointerfaces, 2010